top of page

Let’s Talk About Abs

Public·11 members

Buy Redux Diet Pills ##TOP##

Redux, when combined with a reduced-calorie diet, has been indicated for the management of obesity, including weight loss and maintenance of that weight loss. The safety and effectiveness of Redux beyond one year have not been determined at this time.

buy redux diet pills


In a large, one-year clinical trial of more than 900 subjects, individuals taking Redux in conjunction with a reduced-calorie diet loss significantly more weight than subjects on diet and placebo. Redux helped produce a significant reduction in weight during the first four to six months. This response was maintained during a year of therapy. At the end of the year, 64 percent of all subjects lost at least 5 percent of their initial total weight, 40 percent lost at least 10 percent and 21 percent lost at least 15 percent. In a study of 60 obese subjects who had successfully lost weight by dieting alone (i.e., lost at least ten pounds in the previous year), the addition of Redux to their regimen resulted in the further loss of 2 percent of initial excess weight.

While the FDA approved fenfluramine and phentermine for separate use, the agency never approved them to be used in combination with one another. Even without FDA approval, Fen-Phen gained immense popularity as a wonder drug that could help people lose weight faster than diet and exercise.

In the early 1970s, fenfluramine was developed to treat obesity, but it only achieved minor results, and patients complained of nausea, anxiety, and other uncomfortable side effects. The drug was manufactured by American Home Products under the brand name Pondimin, but because it was not well received by patients, it failed to catch on as a suitable alternative to diet and exercise.

Kathleen, who in the past lost 70 pounds with Weight Watchers and kept it off for six years, took the anti-obesity pills for three weeks. She found her energy was zapped, and she felt constantly fatigued. The scale told her she was up 11 pounds, not down.

Educating people on the risks of taking diet pills is an important component of any program, and Dr. Danial Baker, a pharmacy professor at Washington State University at Spokane, warns that people should be cautious about taking diet drugs such as fen/phen and Redux.

That happened to Devon Croston, a Spokane administrative assistant from Post Falls. She took fen/phen for six months and lost 35 pounds. When she stopped, she gained 25 pounds of that back. Now she is back on the pills.

Despite the nearly constant stream of body-perfect imagery and information, Americans were doing less and less to improve their weight. According to a 1990 Gallup Poll, "Mirror of America," although 62 percent of women and 42 percent of men said they had the desire to lose weight, only 18 percent were actively trying to diet -- a figure that had not changed in 40 years, despite a large increase in the percentage of people dissatisfied with their weight. The NIH panel cited data finding that people who did try dieting would regain one- to two-thirds of the lost weight after a year, and after five years nearly all of the weight would come back.

In 1990s America, women, in particular, were looking for a solution, and the food industry was quick to oblige with new low-fat varieties of consumer products, from potato chips to tomato soup. By 1994, Snackwells reduced-calorie chocolate creme sandwich cookies had replaced Oreos as the nation's most popular cookie. If dieting was doomed to fail, then perhaps switching to reduced-fat versions of junk food would succeed. After all, why go to the trouble of healthy eating and exercise to lose weight if there's a painless short-cut available?

In 1983, a University of Rochester pharmacologist named Michael Weintraub postulated that fenfluramine could be combined with the diet drug phentermine, a stimulant which would counter-balance Pondimin's negative effects. He ran a four-year study, funded in part by the NIH, on 121 subjects averaging 200 pounds, and found that the combination led to the loss of about 32 pounds on average. By 1992, the medical community was formulating its stance on obesity as a chronic disease, and in the wake of the study's report in the Journal of Clinical Pharmacology that same year, doctors began prescribing the fenflurmine-phentermine cocktail, or "Fen Phen," as an "off-label" combination (meaning it was not approved by the FDA).

Dr. George Bray, M.D., a professor at Louisiana State University, made remarks to the IOM meeting regarding the risks and benefits of current drug treatments. He stressed that because obesity is a stigmatized condition, it is unique from other diseases like hypertension for which people take medication. "The cosmetic purposes set a higher standard for safety than for drugs for which the cosmetic purpose doesn't exist," said Dr. Bray. He found that most physicians opt to treat the medical conditions that are associated with or caused by obesity, rather than the condition itself, because the available treatments for those are better. The two diet drugs on the market at that time, orlistat (Xenical) and sibutramine (Meridia), could achieve results of up to 10 percent weight loss -- the highest one can expect from any weight-loss treatment other than surgery, according to Dr. Bray. He estimated that no more than 2 percent of the obese population was taking anti-obesity drugs.

Similar to fenfluramine in that it affects serotonin levels in the body, Meridia was approved about two months after Redux and Pondimin were pulled from the market in 1997. At the time of its approval, it was known to be associated with high blood pressure and increased heart rate. On Sept. 3, 2003, Public Citizen called on the FDA for a second time to withdraw Meridia and sent out a press release citing evidence, culled from the FDA's database, of 49 cardiovascular deaths and 124 adverse cardiovascular reactions in people taking Meridia. The group also says Meridia has an impact on developing fetuses. As America continues to struggle with obesity, it appears the search for a healthy diet drug continues.

As with any diet aid supplement, Redux cannot make up for poor eating habits and a lack of exercise. This supplement is designed to help support your holistic approach to weight loss that includes a healthy diet and plenty of physical activity.

It is important to have realistic expectations. Weight loss supplements can have a real impact, but they are only meant to be one part of a holistic approach to managing your weight that includes a healthy diet and plenty of exercise.

Redux (chemical name, dexfenfluramine) became the first appetite suppressant approved in the United States in 22 years and the first ever for long-term use. It tricks the dieter into feeling full by raising the level of serotonin in the brain.

The FDA had balked at approving diet drugs over the years because they were addictive or caused too many side effects. But researchers said that for the majority of people, Redux is safe on both counts.

All three drugs have been proven to produce heart valve defects and Primary Pulmonary Hypertension (PPH). A non-invasive ultrasound examination called an echocardiograph can detect defective heart valves. People who have developed these conditions after taking diet drugs may be eligible for compensation. In the United States there are between 500 and 1,000 new cases of PPH diagnosed each year. In 1999, American Home Products Corporation (maker of Fen Phen) paid a $3.75 billion settlement to thousands of users of the product who contracted some type of heart disease. The total cost of liability associated with Fen Phen is expected to exceed $14 billion.

Thousands of people suffered serious heart and/or lung damage after taking the diet drugs fenfluramine (Pondimin) or dexfenfluramine (Redux). Levin Sedran & Berman served as Co-Lead Counsel in the Fen-Phen (Diet Drugs) litigation, a case that resulted in a class settlement valued at over $7.65 billion.

Dr. Weintraub tested the combined use of fenfluramine and phentermine in 121 subjects who started on a weight-reduction diet program. After six weeks, the subjects were divided into two groups, the control group and the Fen-Phen group. After seven months, the group receiving the Fen-Phen showed significant weight loss in 80% of subjects compared to the control group still using conventional weight-reduction measures. The average weight loss for the Fen-Phen group was three times as large as the control group. Dr. Weintraub continued the study and placed all participants on Fen-Phen. Significant weight loss was reported. When subjects were randomly selected to be given a placebo instead of the Fen-Phen, they regained weight. Some participants who showed little or no weight loss on the original dosage schedule started to lose weight at a higher dose. By the end of the study, Dr. Weintraub reported that 80% of the participants who had been on the Fen-Phen diet for four years had lost 16% of their total body weight (an average of 34 pounds each). Weintraub, et al., "Longterm Weight Control Study," published in Clinical Pharmacology and Therapeutics, 51(5): 586-646 (May 1992).

On the same day that Dr. Connolly delivered her speech, the FDA issued a news release alerting physicians to the reports of valvular heart disease in women treated with a combination of fenfluramine and phentermine. The FDA stated that "[t]hese are drugs that should be taken only by obese patients in conjunction with a weight loss regimen that includes a reduced-calorie diet and an exercise program, in accordance with approved labeling." "Health Advisory On Fenfluramine/Phentermine For Obesity," FDA Public Health Advisory (July 8, 1997). In addition to the women cited in the Mayo Clinic study, the FDA noted that it had received reports of 33 cases of unusual abnormalities in mitral, aortic, and tricuspid heart valves in women between the ages of 30 and 72 who had been taking fenfluramine and phentermine for one month to 28 months. The FDA pointed out, however, that there was no conclusive evidence of a cause-effect relationship between use of the drugs and the development of valvular disease. 041b061a72


Welcome to the group! You can connect with other members, ge...
bottom of page